Melatonin, a circadian molecule secreted by the pineal gland, confers a protective role against
cardiac hypertrophy induced by
hyperthyroidism, chronic
hypoxia, and
isoproterenol. However, its role against pressure overload-induced
cardiac hypertrophy and the underlying mechanisms remains elusive. In this study, we investigated the pharmacological effects of
melatonin on pathological
cardiac hypertrophy induced by transverse aortic constriction (TAC). Male C57BL/6 mice underwent TAC or
sham surgery at day 0 and were then treated with
melatonin (20 mg/kg/day, via
drinking water) for 4 or 8 weeks. The 8-week survival rate following TAC surgery was significantly increased by
melatonin.
Melatonin treatment for 8 weeks markedly ameliorated
cardiac hypertrophy. Compared with the TAC group,
melatonin treatment for both 4 and 8 weeks reduced pulmonary congestion, upregulated the expression level of α-
myosin heavy chain, downregulated the expression level of β-
myosin heavy chain and
atrial natriuretic peptide, and attenuated the degree of cardiac
fibrosis. In addition,
melatonin treatment slowed the deterioration of cardiac contractile function caused by pressure overload. These effects of
melatonin were accompanied by a significant upregulation in the expression of
peroxisome proliferator-activated receptor-gamma co-activator-1 beta (PGC-1β) and the inhibition of oxidative stress. In vitro studies showed that
melatonin also protects against
angiotensin II-induced cardiomyocyte
hypertrophy and oxidative stress, which were largely abolished by knocking down the expression of PGC-1β using
small interfering RNA. In summary, our results demonstrate that
melatonin protects against pathological
cardiac hypertrophy induced by pressure overload through activating PGC-1β.